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ABSTRACT
Within the past years there have been substantial changes to our understanding 
of haematopoiesis and cells that initiate and sustain leukemia. Recent studies have 
revealed that developing haematopoietic stem and progenitor cells are much more 
heterogeneous and versatile than has been previously thought. This versatility 
includes cells using more than one route to a fate and cells having progressed some 
way towards a cell type retaining other lineage options as clandestine.  These notions 
impact substantially on our understanding of the origin and nature of leukemia. An 
important question is whether leukemia stem cells are as versatile as their cell of 
origin as an abundance of cells belonging to a lineage is often a feature of overt 
leukemia. In this regard, we examine the coming of age of the “leukemia stem cell” 
theory and the notion that leukemia, like normal haematopoiesis, is a hierarchically 
organized tissue. We examine evidence to support the notion that whilst cells that 
initiate leukemia have multi-lineage potential, leukemia stem cells are reprogrammed 
by further oncogenic insults to restrict their lineage decision-making. Accordingly, 
evolution of a sub-clone of lineage-restricted malignant cells is a key feature of overt 
leukemia.
INTRODUCTION
An important question regarding stem and progenitor 
cells choosing a developmental route is whether the routes 
these cells follow to a mature cell type are invariant or 
versatile. By versatility, we mean the extent to which 
there are alternative pathways to a cell type and whether 
cells that have developed part of the way along a lineage 
pathway can be diverted along a different lineage pathway. 
In this case, the alternative pathway fate options might 
be viewed as clandestine. Overall the question is one of 
mutability of cell fate: in other words, the extent to which 
cells can readily reprogram their lineage potential(s). In 
1987, Shankland described flexibilities to developmental 
pathways in the embryo of the leech [1]. Cells can use 
alternative pathways to give rise to an end cell phenotype 
and this versatility can also be latent. Neurons and 
epidermal specifications normally descend from the 
‘p blast’ group of precursors, but when the ‘p blast’ lineage 
is ablated the ‘o blast’ cells then give rise to neurons and 
epidermal cells. This adaptation of the ‘o blast’ cells to 
a new pathway means that lineage pathways are open to 
reprogramming during normal leech development.
Strikingly similar findings have emerged from 
recent studies of mouse stem cells. Studies by Chan and 
co-workers have shown that quite unexpected cell types 
can alter their lineage fate [2]. Cells residing within 
the femoral growth plates of bone and that express the 
haematopoietic cell surface marker Tie2 are not able to 
form bone, cartilage or stroma. Adipose tissue contains 
high numbers of Tie2+ cells and collagen sponges 
containing recombinant bone morphogenic protein 
2 (BMP-2) were inserted into the inguinal fat pad of a 
reporter mouse (Tie2Cre x MTMG) that labels Tie2 cells 
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with GFP and other cells with RFP. Ossicles provoked 
by BMP-2 and harvested a month later contained 
Tie2-derived (GFP positive) and Tie2-negative-derived 
(RFP positive) osteocytes, indicating both these cell 
populations had undergone a shift to a skeletal fate. The 
use of a parabiont model (actin-GFP transgenic/non-GFP 
congenic) showed that circulating cells had not contributed 
to the BMP2-driven formation of ectopic bone. In essence, 
BMP-2 appears to have reprogrammed Tie2+ and Tie2− 
cells resident in the extra-skeletal site, inferring flexibility 
in the programme status of these cells. These data also 
highlight the importance of environmental niches to the 
regulation of choice of lineage pathways.
The heterogeneity and versatility of 
haematopoietic stem and progenitor cells
The mammalian blood cell system provides 
developmental biologists with one of the best models 
for unravelling how a stem cell – the haematopoietic 
stem cell (HSC) – gives rise to the many different types 
of cells of the blood and immune systems. Information 
gained about the nature of cell compartments to 
developmental progression led to definition of the 
cellular origins of the various types of leukaemia. The 
haematopoietic and skeletal systems have a similar 
architecture, adhering to a multi-potent stem cell giving 
rise to a variety of well-compartmentalised down-stream 
progenitors that are becoming progressively restricted in 
their lineage capacities. In recent years, our viewpoint 
on the architecture of haematopoiesis has changed to 
take into account the idea that haematopoietic stem 
and progenitor cells (HSPC) are more versatile than 
previously thought [1, 3, 4].
Since the 1980s, the model generally used to 
describe haematopoiesis is an invariant cell lineage tree 
for developing progenitor cells. The tree depicts a series 
of binary decisions [5]. The first of these is the HSC 
makes an immediate, and irrevocable, choice between 
the myeloid and lymphoid pathways of development, 
as evidenced by the existence of a common myeloid 
progenitor (CMP) and common lymphoid progenitor 
(CLP) (Figure 1A) [6, 7]. CMP and CLP follow preferred 
routes to a particular cell fate; with these evidenced by 
colony-forming cells (CFC) which give rise to certain 
types of mature cells when bone marrow cells are 
dispersed in semi-solid medium. These include, colonies 
containing a variety of cell types, for example, granulocyte/
erythrocyte/ megakaryocyte/ macrophage-CFC. Colonies 
containing only two types of cells such as granulocyte/
monocyte-CFC identify a bipotent granulocyte/monocyte 
progenitor cell (GMP).
Whether the ‘classic’ model is an accurate 
depiction of haematopoiesis has been questioned by the 
identification of sub-groups of haematopoietic progenitor 
cells (HPC) with lymphoid potentials and only a sub-set of 
myeloid potentials. These cells include early progenitors 
with lymphoid and myeloid potential (EPLM) [8] and 
lymphoid-primed multipotent progenitors (LMPP) [9] 
which have lymphoid potentials and myeloid potentials 
excluding those for erythroid and megakaryocyte 
development. The identification of EPLM and LMPP 
excludes a strict schism as to separate programming 
of myeloid and lymphoid fates as HSC do not pass 
through an obligatory CMP versus CLP phenotype [10] 
Whilst EPLM and LMPP preclude this strict dichotomy 
they do not contravene the clear existence of CMP and 
CLP. Instead, the main point is that the combination of 
partial myeloid fates and lymphoid fates within EPLM 
and LMPP span the fate potentials of CMP and CLP, 
respectively. To extend this notion, there might well 
be a plethora of intermediate HSC-derived HPC with 
different combinations of differentiation options. The 
options available to HPC have been revealed using in vitro 
clonogenic assays and by the extent to which cell lines 
that typify immature cells can be manipulated by culture 
conditions (growth factors, retinoids and phorbol ester) 
to differentiate along various pathways [reviewed in 3]. 
Indeed, there is a striking array of progenitors and cell 
lines with different combinations of lineage options. To 
add to this variability, many of the known HPC that are 
viewed as homogenous might be an admixture of cells 
and markers are lacking to resolve sub-populations. The 
use of a combination of markers and of in vivo assays has 
revealed HSC to be a heterogeneous population of cells: 
HSCs that are platelet-, myeloid- and lymphoid-biased 
have been described [11–14].
In addition to sub-dividing HSC, the presence of 
lineage biases within these cells brings to attention two 
interesting notions. First, the biases having originated 
in HSC might be presumed to persist in their progeny. 
In keeping with this, new markers and combinations of 
markers are likely to reveal such heterogeneity within 
HPC. Second, HSC appear to display a developmental 
propensity to differentiate readily and irrepressibly 
diversify and differentiate. In fact, they do so when 
cultured with appropriate growth and survival factors and, 
as considered later, some of these growth factors instruct 
fate adoption.
Whilst fate options occur in varied combinations 
there is order to the sets of fates available to individual 
cells. Our own viewpoint on haematopoiesis is to not draw 
strict lines representing routes from HSC via their progeny 
to end cell types. The pair-wise model shows a series of 
invariant pair-wise developmental relationships, with the 
fate choices available to HSC as a continuum [10] (Figure 
1B). The ordering of near-neighbours relates to the sets 
of potentials available to various known oligopotent HPC 
[reviewed in 3, 10], as represented by the arcs in the figure. 
The pair-wise model accommodates lineage-biased HSCs 
that are platelet-, myeloid- and lymphoid-biased which are 
also interesting as to targets for transformation in leukaemia.
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Multiple routes, clandestine options and lineage 
reprogramming
Direct evidence to support the notion that progenitor 
cells can use more than one route to generate a type of 
mature cell comes from the experiments undertaken by 
Ishikawa and co-workers [15]. These workers purified CLP 
and CMP and derived dendritic cells (DC) in vitro from 
both the cell populations. The transcription profiles of the 
two DC populations were the same, supporting alternative 
lymphoid and myeloid routes to DC. Less direct support 
comes from examining the fates available to various 
progenitors and configuring the number of possible routes 
to an end cell type by virtue of which progenitors are or 
are not able to give rise to one another [reviewed in 3]. 
Using this approach, the known and possible routes for 
the development of neutrophils and monocytes are shown 
in Figure 2. For example, pathways to mature neutrophils 
Figure 1: Schematic representations of haematopoiesis. (A) Depicts the classic model in which the haematopoietic stem cell makes 
an irrevocable choice between the myeloid and lymphoid pathways. (B) Depicts the pair-wise model. Differentiation options are envisaged 
as a series of invariant pair-wise developmental relationships with cells becoming gradually biased towards producing one cell type 
or another.
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Figure 2: Alternative routes to dendritic cells, neutrophils and monocytes. (A) The alternative routes to dendritic cells relate 
to the generation of these cells from either the common myeloid progenitor or the common lymphoid progenitor. (B) and (C) Routes to 
neutrophils and monocytes are either known routes from studies of progenitor cells (solid lines) or inferred by virtue of which known 
progenitors are or are not able to give rise to one another regardless of whether such has been traced.
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include via LMPP, which have lymphoid in addition to 
myeloid potentials, and via CMP, which do not give rise 
to lymphocytes.
Some of the new models that challenged a 
lymphoid/myeloid dichotomy depict more than one route 
to an end cell type. In redefining lymphoid progenitors 
in 2002, Katsura mapped myeloid cells arising from a 
myeloid-T-cell progenitor and a myeloid-B-cell-progenitor 
in addition to from CMP [16]. Ye and Graf mapped two 
branches to granulocytes and monocytes, with one largely 
giving rise to granulocytes and monocytes and the second 
giving rise to these cells and platelets and erythroid cells 
[17]. An entirely new way of viewing flexibility of and 
reprogramming of cell lineages was presented in the 
‘myeloid-based’ model by Kawamoto and Katsura [18]. 
These workers proposed HSC follow a ‘prototypic’ 
myeloid developmental pathway and these activities are 
then modified or switched off for HPC to undergo more 
specialised lymphoid development. Though the extent 
various routes are used in vivo remains uncertain, their 
existence supports the notion of lineage versatility.
Commensurate with the notion of multiple routes 
is HPC that have developed some way along a pathway 
retain other fates as clandestine options. This is best 
illustrated by the development of progenitors from 
bone marrow that seed the thymus to undergo T cell 
development, termed thymus-settling progenitors (TSP). 
These cells can give rise to B lymphocytes, natural killer 
cells, myeloid cells and dendritic cells [19–22], as revealed 
by culturing cells in appropriate conditions. B lymphocyte 
potential is lost early during T cell development, as TSP 
become early thymocyte progenitors (double negative 
(DN) 1 cells). Cells at the DN1 and subsequent DN2 
stages of development can still give rise to natural killer 
cells, myeloid cells and dendritic cells [19–21], with loss 
of these potentials as DN1 progress to the DN3 stage of 
T cell development (Figure 3). Whilst the extent to which 
developing TSP are diverted in vivo is uncertain these cells 
can clearly reprogram their fate.
The importance of environmental signals to 
lineage programming
Not only are HSC and progenitors heterogeneous, 
but they also reside in a variety of microenvironments in 
which they interact with local stromal cells and receive 
signals from cytokines.  These influences are now seen 
to be important to lineage programming of HSPC. The 
strength and duration of environmental signals, such as 
Notch, and presence of haematopoietic cytokines, such 
as macrophage colony-stimulating factor (MCS-F) and 
FLT3 ligand (FLT3L), influence the types of cells that, for 
example, developing thymocyte progenitors and EPLM 
give rise to in vitro. In early studies, whether signals 
consolidated the choice of lineage pathway or were 
instructive was unclear. Haematopoietic cytokines have 
long been viewed as providing signals for cell survival 
and proliferation. However, some are now clearly seen 
to instruct lineage fate decisions. Recently, Tsapogas 
and co-workers have shown that a certain threshold 
level of FLT3L drives multipotent progenitors towards 
myeloid/lymphoid fates at the expense of megakaryocyte/
erythroid fates [22].  For many years, Metcalf championed 
instructive roles for granulocyte/macrophage colony 
stimulating factor (GM-CSF) and macrophage colony 
stimulating factor (M-CSF) in guiding granulocyte/
macrophage colony forming cells towards granulocytes 
and macrophages, respectively [23]. In 1991, he showed 
a combination of GM-CSF or multi-colony stimulating 
factor, with stem cell factor, increased the frequency of 
granulocyte progenitors in blast cell colonies established 
from normal bone marrow cells [24]. In 2009, Reiger 
Figure 3: Developing thymus-settling progenitors retain clandestine options. The sets of fate options available to thymus-
settling progenitors as they differentiate towards T lymphocytes are shown by the arcs. They are revealed by culturing cells in appropriate 
conditions.
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and co-workers confirmed instructive roles for M-CSF 
and G-CSF by showing these cytokines instruct 
individual GMP to adopt monocytic or neutrophilic fates, 
respectively [25]. M-CSF also instructs some long term-
HSC (LT-HSC) to express myeloid associated genes 
[26]. Erythropoietin instructs erythroid fate as revealed 
by skewing of the potential of LT-HSC towards this fate 
and priming of erythroid lineage-associated genes in these 
cells [27].
As outlined above, the architecture of the 
haematopoietic system is far less compartmentalised 
and more complex, particularly in terms of lineage 
versatility, than previously thought. Developing HPC can 
use alternative pathways and have clandestine potentials, 
indicating that the natural propensities of HSPC are to 
diversify and versatility. This is in keeping with most 
of biology is Darwinian in nature. The presence of 
lineage biases within HSC might well extend to known 
HPC with each being a mixture of cells with differently 
biased differentiation capacities. Moreover, developing 
haematopoietic cells appear to be gradually biased towards 
producing one cell type or another which transforms our 
view of the nature of commitment in HSPC. In other 
words, lineage commitment isn’t a stepwise all-or-none 
event, whereby pluripotent and/or oligo-potent populations 
of cells continuously produce committed offspring. And 
importantly, the biases can be overridden by environmental 
factors. All of the above have implications to the origins 
of and progression of malignant transformation. Below we 
examine whether transformed cells adhere to the above 
tendencies or have a more restricted phenotype overall.
The architecture of leukemia: haematopoiesis 
and leukemia are both hierarchically organized 
processes 
In the last years, we have seen the coming of 
age of the “leukemia stem cell” (LSC) theory. This 
has led to leukemia as a hierarchically organised 
process and renewed interest in whether aberrant cell 
differentiation lies at the root of cancer. From this point 
of view, a comprehensive knowledge of the aberrations to 
developmental mechanisms whereby normal target cells 
acquire this tumor characteristic is essential to understand 
leukemia [28]. Cytogenetic and molecular genetic 
analyses have defined genetic events that are consistently 
associated with each of the various types of cancer 
[29]. Particular genetic alterations are associated almost 
exclusively with a subgroup of human cancer that has a 
distinct phenotype (Figure 4). These genetic lesions are 
of clinical importance, and they may serve as unequivocal 
diagnostic markers, but they have also provided important 
clues to the cellular mechanisms behind leukemia 
development. The genotype-phenotype correlations 
established in human leukemias have demanded during 
the last three decades that we explain the nature of the 
intimate association between each genetic lesion and the 
phenotype (particular type of leukemia) with which it is 
associated [30]. 
Two different hypotheses have been considered to 
explain the link between genotype and the set phenotype 
of tumor cells (Figure 5). In the classical view of the 
initiation and progression of leukemia, an initiating 
Figure 4: Genotype-phenotype correlations are established in human leukemias. The expression of each one of the genetic 
lesions associates almost exclusively with a characteristic subgroup of human leukemias.
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genetic alteration takes place that is required for the 
immortalization of a committed/differentiated target 
cell (Figure 5B). Such cells will afterwards acquire 
additional genetic hits over time. The acquisition of 
additional hits aggravates the deregulation of the behavior 
of the differentiated target cell, leading to the clinically 
recognized features of leukemias. This is the model that 
has traditionally underpinned the study of leukemogenesis 
and takes for granted that the phenotype, in terms of the 
differentiated attributes of the tumor cells, reflects that 
of the normal cell that gave rise to the tumor in the first 
place. In most cases, cancerous cells do share similarities 
with non-pathological differentiated cell types. Therefore, 
for every kind of cancer, the cell of origin was assumed 
to be the corresponding normal differentiated cell. 
However and for some time, there have been some 
classical examples in which this is clearly not the case. 
Chronic myelogenous leukaemia (CML) presents as an 
abundance of relatively mature neutrophils and Fialkow 
and colleagues suggested nearly 40 years ago that this 
disease arises from transformation of a rare HSC. The 
evidence for this is the t (9;22) chromosomal translocation 
which typifies CML and can be found in most types of 
differentiated haematopoietic cells in patients [31]. 
During the chronic phase of CML the malignant stem cell 
clone is channelled towards producing neutrophils, and, 
in essence, the non-myeloid cells are not behaving in a 
malignant and clonally expansive manner. Another way of 
interpreting the genotype-phenotype correlations observed 
between genetic lesions and a given tumoral phenotype 
is to consider the possibility that the oncogene is directly 
responsible for imposing the specific characteristics of the 
leukemia phenotype (Figure 5C).
Leukemogenesis: an inappropriate lineage-
decision making process
There are striking findings that suggest that tumoral 
reprogramming and aberrant lineage-programming 
are key features of the origin of cancers and leukemias. 
Malignant glioblastoma neural stem cells can be 
reprogrammed to induced-pluripotent stem cells (iPSC). 
These iPSC can differentiate into mesodermal lineages, 
and when they do so they lose their malignant nature, but 
they maintain their malignant status when they differentiate 
along neural pathways [32]. Similarly, the differentiation 
block is overcome in primary human Philadelphia 
chromosome-positive B cell acute lymphoblastic leukemia 
(B-ALL) cells by reprogramming cells into non-leukemic 
macrophages [33]. The importance of these findings is 
that the malignancy status is somehow linked to the cells 
having been programmed to adopt a lineage pathway. Key 
questions are the developmental stage, as to stem and/
or progenitor cells, which is being programmed to this 
effect and at what stage does this occur in relation to the 
progression of the development of leukemia.
During leukemogenesis a normal cell acquires a 
new but inappropriate (malignant) identity to give rise to 
a clonal aberrant population. This is only possible if the 
normal cell that gives rise to the leukemia, the leukemia 
cell-of-origin (LOC), has the necessary plasticity to 
undergo change. Also, the oncogenic event(s) initiating 
cancer must have an inherent reprogramming capacity, 
to be able to lead to the change in cellular identity [28]. 
The molecular mechanisms underlying this aberrant 
decision-making process are the pathological aberrations 
of the normal processes that regulate the developmental 
programming and plasticity of cells and that must operate 
to drive experimentally-induced reprogramming of mature 
cells to iPSCs. As to the capacity of an oncogenic insult 
to reprogram cells, it is generally accepted that tumoral 
progression is a multi-hit process. In this case different 
aspects of normal cellular biology are progressively 
altered to finally give rise to a full-blown tumor [34]. As 
mentioned above, developing normal HSPC are guided 
towards lineage biases, diversifying and differentiating 
towards their end-stage cells. The multi-hit requirement 
for full tumor development can be related to the notion 
that changes which are necessary for reprogramming cells 
to reverse a differentiated state to full pluripotency are 
inherently disfavoured developmentally. In both cases, 
biological barriers exist to prevent cells from changing 
their identity in this manner in order to avoid the risk of 
malignant transformation.
Evidence to support the inherent resistance of 
normal cells to reprograming by an oncogene to a tumour 
phenotype comes from recent studies of stem-cell based 
animal models of human cancer. Loss of p53 is a frequent 
occurrence in malignancy and facilitates pathological 
reprogramming to a malignant phenotype as follows. In 
a stem-cell based transgenic model of multiple myeloma, 
the loss of p53 accelerated the appearance of disease 
by allowing the MafB oncogene to drive a much more 
efficient malignant transformation [35, 36]. Something 
similar happens in the case of mucose-associated lymphoid 
tissue (MALT) lymphoma that is driven by the MALT1 
oncogene [37]. As to restoring activity of p53 protein 
and the effect on malignancy, a sophisticated approach 
has been the use of a knock-in mouse model carrying the 
modified p53 protein p53ERTAM. This can be switched on 
and off in vivo by tamoxifen administration or withdrawal, 
respectively. In a stem-cell based model of CML [38], 
restoration of p53 activity slowed the progression of the 
disease and extended the survival of leukemic animals by 
inducing the apoptotic death of primitive leukemic cells.
The relevance of reprogramming and lineage 
decision-making to malignancy is also illustrated by 
consideration of the action of retinoic acid receptors 
(RARs), particularly RARγ. These receptors, for the 
natural ligand all-trans retinoic acid, have long been 
known to play important roles during development. 
The oncogenic potential of RARγ was revealed by 
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studies of hepatocellular carcinoma [39]. As to a link 
to lineage reprogramming, addition of RARγ to the 
four transcription factors (Oct4, Sox2, Klf4 and c-Myc) 
used to reprogram somatic cells to iPSCs cells greatly 
accelerated reprogramming of mouse embryonic 
fibroblasts [40]. The importance of activity of RARγ 
to decision-making by stem cells is seen in studies of 
zebrafish development. Treatment of zebrafish embryos 
with a RARγ-specific agonist adversely affected the 
development and growth of tissues that form from neural 
crest and lateral plate mesodermal stem and progenitor 
cells that express RARγ. These studies revealed that 
RARγ, which can play a role in cell reprogramming, 
has to be inactive at the stem/progenitor stage of 
development for these cells to make an appropriate 
decision to differentiate along a pathway [41].
The cell of origin in leukemia
Accepting that leukemia is a hierarchically 
organized tissue maintained by leukemia stem cells 
(LSCs), it becomes essential to identify the normal cell 
which first suffers the oncogenic alteration that will 
finally lead to the generation of the LSC (Figure 6). 
This LCO must possess sufficient plasticity to allow 
Figure 5: Proposed model for the role of human cancer gene defects in cell lineage specification. (A) During haematopoiesis 
a small pool of multipotent stem cells maintain multiple cell lineages. (B) Traditionally, human leukemia genetic defects have been 
thought to act on cells already committed to a differentiation program. Hence, the leukemia phenotype closely resembles that of the 
initial differentiated target cell. (C) Normal uncommitted stem and progenitor cells are the targets for transformation in some human 
leukemias and the human leukemia-gene defects into these cells are the instigators of lineage choice decisions. Consistent with this is forced 
expression of these genes in stem cells can select or impose a specific leukemic-lineage outcome. This explains why specific gene defects 
are found only in one type of leukemia (see text for details).
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the tumoral reprogramming to take place or, at 
least, to be initiated. The characteristics of the final 
leukemia will be the result of the interaction between 
the reprogramming capacity of the oncogene(s) and 
the susceptibility of the LCO to reprogramming. As 
mentioned above, it was assumed that the phenotype 
of the leukemia cells reflects that of the normal cell 
from which they originated [30], and that, therefore, 
the characteristics of leukemia cells were more or less 
a caricature of their cell of origin. Accordingly, the 
cell of origin was always sought among those most 
similar to the cancerous one. However, all the evidence 
accumulated over the last years has led to a different 
point of view that leukemias are a stem cell-based tissue 
[42–44]. In this case, only some of the cells within the 
tumor, namely the LSC can regenerate the leukemia 
mass and the phenotype of the tumoral differentiated and 
partially differentiated cells might be largely unrelated 
to the cell that originates the LSCs. The LCO would be 
the cell by the process of tumoral reprogramming that 
will finally lead to the generation of the LSC which is 
the only one that can (re)generate the tumor.
One option is that LSCs could have their origin 
in normal stem cells, maintain stem cell properties and 
become pathologically reprogrammed via a mutational 
event (Figure 6). In the case of CML, the tumor-driving 
mutation is the chimeric oncogene BCR-ABLp210. It has 
long been known that BCR-ABLp210 is present in all the 
hematopoietic lineages and can also be traced back to their 
HSCs. Importantly, the oncogenic effect only manifests in 
the myeloid lineages, at least during the chronic phase [45]. 
The stem cell origin of CML has been recently confirmed 
using a stem-cell based animal model in which expression 
of the BCR-ABLp210 oncogene is restricted to the stem 
cell stage of development in a genetically engineered 
mouse [43, 46]. Despite this restricted expression 
window, BCR-ABLp210 induces a full-blown CML in 
the mice, with all the cellular and tissue characteristics of 
the human disease including cells differentiating towards 
neutrophils. Importantly, the differentiated CML cells do 
not express the oncogene but have a tumoral phenotype, 
therefore indicating that tumoral reprogramming took 
place at an earlier developmental level [43, 46]. Similarly, 
in transgenic mice in which the expression of different 
oncogenes is restricted to the stem/progenitor cells, 
mice develop specific leukemias/lymphomas that very 
closely recapitulate the main features of human disease 
[36, 37, 46–48]. However, heterogeneity seems to be 
Figure 6: A new concept of the human leukemia as a result of a restriction of lineage options during stem cell 
transformation. (A) Scheme of the normal differentiation program from stem cells. Normal stem cells give rise to transit cells which 
expand to give rise to terminally differentiated cells. (B) Human leukemia is a genetic disease originated by several possible types of 
genetic/epigenetic alterations. LSC give rise to transit-amplifying cells that would expand and originate the main and highly expansive 
tumor cell mass. All human leukemic cells carry the oncogenic alteration, from the cell-of-origin to the more differentiated cancer cells, 
though the role of this oncogene may be different at different stages of leukemia differentiation, and these mutations might become carrier 
mutations rather than driving ones depending on the cellular context. (C) Based on the reprogramming nature of oncogenes, restricting 
expression of the oncogenic alterations to the stem cell compartment is all that is needed to recapitulate the heterogeneity of leukemia. 
Using a stem-cell restricted transgenic expression system, the expression of the oncogene in the reprogramming-prone stem cells and 
progenitors allows the development of all of the cells that compose the leukemia mass. The modified gene is present in all the mouse cells 
but the oncogene impact is limited to the stem/progenitor compartment. This is similar to what happens in other cases of reprogramming, 
where the reprogramming factor(s) does not need to be present anymore once the initial fate-inducing change has taken place 
(for example, induced pluripotency).
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restricted to the initial stages of chronic leukemia and 
tumors and importantly sub-clones mainly determine 
tumor progression and therapeutic outcomes [49, 50].
Further support to the notion that leukemias largely 
arise from stem cells is their longevity predisposes to 
malignant transformation. Recent advanced technologies 
including next-generation sequencing analysis have 
enabled us to identify frequently occurring somatic 
mutations in many hematological malignancies including 
leukemias and lymphomas [51–69]. It is important to 
note that only cells with a long lifespan can accumulate 
these mutations. In regard to haematopoiesis, the HSCs 
are the main critical cellular targets and it is known that 
the number of acquired somatic mutations in HSC 
increase with age [70]. HSCs carrying these mutations can 
produce a number of myeloid or lymphoid progenitors that 
have identical abnormalities and these progenitors can 
be the final target for the transformation of LOCs into 
LSCs in acute leukemia [71]. As outlined above, the BCR-
ABLp210 fusion protein can drive HSCs to give rise to 
the chronic phase of CML. However, during myeloid 
blast crisis in CML, additional genetic abnormalities 
can transform GMP into LSCs. In t (8; 21) AML, the 
AML1–ETO fusion is found in HSCs; these AML1–ETO+ 
HSCs can differentiate into mature blood cells [72, 73]. 
Additional KIT mutations at the GMP stage seem to be 
critical for the formation of AML LSCs [74]. Furthermore, 
next-generation sequencing analyses have shown that 
pre-malignant clones carrying somatic mutations have 
been frequently found in HSCs of patients with AML 
without specific chromosomal abnormalities [75, 76]. 
Thus, HSCs are a reservoir for mutations at least in 
myeloid malignancies [77].
In contrast, the involvement of HSCs had not 
been considered in lymphoid malignancies within the 
recent past. However, it has been reported recently 
that in mature lymphoid malignancies, such as chronic 
lymphocytic leukemia (CLL), the cellular propensity for 
clonal B cell development has been achieved at the HSC 
level [78, 79]. And, the genetic alterations specific for 
T cell lymphoma [80, 81], follicular lymphoma [82, 83] 
and hairy cell leukemia [84] can be traced back to the 
HSC stage. These studies have suggested that even in 
relatively mature lymphoid malignancies, human HSCs 
could be the reservoir for genetic mutations, which 
constitutes a prime source for lymphoid malignancy 
development. The outcomes are cells that are veered 
towards particular developmental pathways. In addition 
to the detailed analysis of LCO in primary human 
lymphoid malignancies, murine models of mature B-cell 
malignancies have been successfully established by 
targeting HSCs; the ectopic expression of disease-specific 
oncogenes such as BrafV600E, MALT1, MafB, HGAL, and 
Bcl6 within HSCs successfully reproduces the nature of 
the mature lymphoid malignancies [36, 37, 47, 48, 84]. 
Importantly, when these oncogenes have been expressed 
within cells committed to the B-cell lineage the mice 
failed to develop the lymphoid malignancy. These studies 
support the hypothesis that mature lymphoid malignancies 
may be initiated by an inappropriate lineage-decision 
making process at the HSC level.
Restriction of lineage options during stem cell 
transformation
Normal HSCs are characterized by their multilineage 
differentiation potential. The pre-LSCs of many leukemias 
exhibit multilineage potential and differentiation, as 
mentioned above, pre-LSC CML associated with BCR-ABL 
fusion exhibit multilineage differentiation whereby mature 
granulocytes, monocytes, erythrocytes, platelets and B 
lymphocytes are all part of the malignant clone (Figure 7A). 
Similarly, in CML associated with a mutant RAS allele, 
the mutant RAS can be found in granulocytes, monocytes, 
B lymphocytes and T lymphocytes, indicating also the 
presence of a multipotent pre-LSC. In myelodysplastic 
syndromes, a multipotent malignant stem cell is implicated 
in patients with refractory anemia (RA), RA with ringed 
sideroblasts or RA with excess blasts.  The presence of 
pre-LSC with multilineage differentiation potential suggests 
the occurrence of initiating mutations in a normal HSC. 
Only upon the acquisition of further mutations the initiated 
LCO evolves to produce a sub-clone of lineage-restricted 
malignant blasts (Figure 7B). This fits with a two-hit 
model of leukemogenesis, which posits the stepwise 
acquisition and collaboration between mutations that 
activate signal-transduction pathways to confer a survival 
or proliferative advantage (e.g. mutations in FLT3, RAS 
or KIT) and mutations in genes coding for transcriptional 
regulators that potentially restrict lineage options (e.g. 
generation of novel oncogenes such as RUNX1-RUNX1T1 
or PML-RARA, BCR-ABLp190, ETV6-RUNX1 or mutations 
in CEBPA, PAX5 or NPM1). In keeping with this are cases 
in which a pre-leukemia lesion exists stably as a single 
aberration in an abnormal cell population that will only 
progress to an open leukemia when secondary hits occur.
Targeted therapies fail to eradicate LSC and the 
prospect of reprogramming these cells 
Current therapies fail to eradicate LSC, in spite 
of their apparent efficacy against the main mass of 
leukemia cells. A possible rationale to this difficulty is as 
follows. Above we have argued that LSC are generated 
by a (leukemia) reprogramming of normal HSC to a set 
(leukemic) phenotype whereby lineage options have been 
restricted. In this case, the triggering agents, the oncogenes 
that initiate leukemia formation, might not be required 
anymore for disease progression once the new circuits 
have been established and the new fate is set [46, 85]. The 
initiating lesion is the driving force in the reprogramming 
process, essential for leukemogenesis. However, once 
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reprogramming and lineage restriction have taken place 
the initiating hit is only a passenger mutation within 
the LSC, either without a significant function anymore 
or even performing a different role, unrelated to the 
reprogramming one, in tumor expansion or proliferation. 
This model can explain why oncogene inhibition through 
targeted therapies would not affect the LSC compartment. 
As a driver to leukemia, reprogramming of HSPC to 
HSC and to a distinct lineage option circuitry presumably 
leads to the establishment of a new epigenetic signature. 
The latter opens a clear hope for treatment as epigenetic 
modifications, unlike genetic changes, can be manipulated 
to erase and/or reverse. Indeed, it has already been proven 
that incorporation of agents that target epigenetic events 
to the standard chemotherapy is a promising approach to 
the treatment of relapsed pediatric acute lymphoblastic 
leukemia [86]. In different experimental settings, the 
results suggest that cancer cells can be reprogrammed to 
a non-tumoral fate, losing their malignancy. For example, 
it is possible to even produce clonal mouse embryos from 
brain tumors [87] and, by using nuclear transplantation, to 
reprogram melanoma cells [88] and embryonal carcinomas 
[89]. As described above, it is clear that reprogramming 
B-ALL cells to an alternative lineage cell fate can suppress 
malignancy. These findings indicate that reprogramming 
tumor cells is a viable prospect. Also, it is to be expected 
that LSCs from different cancer types will share many 
similarities, implying that similar LSC-based therapeutic 
approaches could be used in many different leukemias. 
However, as for any other therapeutic approach, a precise 
knowledge of the epigenetic rewiring is necessary before 
we can attempt a successful intervention. 
Future opportunities and challenges
For the future, there is a biological paradox we don’t 
really understand, in particular the balance between cell 
intrinsic and environmental drivers of certain biological 
processes. Pluripotency, a pre-requisite for versatility, 
underpins the means of an organism to diversify by 
evolving different types of specialized cells. However, 
maintenance of pluripotency is obstructive to the 
embryonic development of a specialized adult organism 
from the amorphous mass of cells that is the early embryo. 
We are moving towards the viewpoint that the architecture 
of normal haematopoiesis is much more versatile and 
plastic than previously thought. These attributes are 
important to responding to the demand provoked by a 
wide variety of infectious agents as to the specialized cells 
required to counteract such. We have postulated leukemias, 
in their full-blown and overt state, are channeled, via 
reprogramming, towards a malignant and more immobile 
phenotype. Do we see that cancer is the price to pay as to 
exacerbation of an inherent and selfish-gene propensity to 
enforce lineage biases which is important to maintenance 
of the overall status quo of the developed adult organism? 
Figure 7: Schematic representation of the emergence of LSCs in human leukemia. (A) A mutation occurs in HSCs leading 
to the emergence of aberrant pre-leukemic HSCs. These aberrant pre-leukemic HSCs self-renew and expand within the HSC compartment. 
Pre-leukemic HSCs give rise to a high number of lineage-committed progenitors harboring the identical mutations. This leads to an 
increased chance of acquiring the additional oncogenic events, which finally transform the aberrant progenitor cells from pre-leukemic 
HSCs into the leukemic stem cells (LSCs). (B) Loss of differentiation potentials is essential for the emergence of LSCs. These sequential 
leukemia progression models are commonly accepted as to the development process of human acute malignancies.
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This ancestral biological drive exists as some organisms 
have remained unchanged for millions of years.
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